top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

497.45 +12.23 (+2.52%)
Delayed Quote Updated: 12:57 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
77 78 Next >
News headline image
Vertex (VRTX) Q1 2026 Earnings Call Transcript ↗
Vertex (VRTX) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Vertex Pharmaceuticals Reports Mixed Q1 Results ↗
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reports financial results for the first quarter after the market close on Monday. 
Via Benzinga
Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q1 Estimates as New Drug Launches Drive Diversification ↗
Via Chartmill
News headline image
Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q1 CY2026 Sales Expectations
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 7.8% year on year to $2.99 billion. ... 
Via StockStory
Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth Stock with Promising Technical Setup ↗
Via Chartmill
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Presents a Compelling Growth and Technical Setup ↗
Via Chartmill
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Prime GARP Investment ↗
Via Chartmill
News headline image
Vertex Reports First Quarter 2026 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex (VRTX) Q2 2025 Earnings Call Transcript ↗
Vertex (VRTX) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Vertex Pharmaceuticals (VRTX) Q1 Earnings: What To Expect
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what investors should know. Vertex Pharmace... 
Via StockStory
News headline image
Got $1,000? Which of These Beaten-Down Healthcare Stocks Is Worth Buying? ↗
These longtime market beaters may not have peaked yet. 
Via The Motley Fool
Topics World Trade
News headline image
Set It and Forget It: 3 Monster Stocks Worth Holding Through Whatever Comes Next ↗
They may suffer the occasional knee-jerk setback. By and large, though, investors understand these companies are capable of standing up to almost any challenge. 
Via The Motley Fool
Topics Credit Cards Economy
News headline image
Want to Build Real Wealth in Healthcare? These Stocks Are Worth Considering ↗
These companies are leaders in their fields. 
Via The Motley Fool
News headline image
What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer. ↗
The biotech's candidate may treat a great number of illnesses that have one thing in common. 
Via The Motley Fool
News headline image
Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead? ↗
This particular player has seen its yield rise in recent years. 
Via The Motley Fool
News headline image
3 Growth Stocks That Could Generate 10X Returns ↗
These stocks come with risk, but they also have some exciting long-term growth opportunities. 
Via The Motley Fool
Topics Cannabis Law Enforcement
News headline image
3 of Wall Street’s Favorite Stocks Worth Your Attention
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
News headline image
3 Market-Beating Stocks to Consider Right Now
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ... 
Via StockStory
Topics Energy
News headline image
3 Healthcare Stocks With the Most Durable Competitive Moats ↗
These companies offer a clear path to sustained earnings growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? ↗
We'll know more about the company's medium-term prospects by the end of the year. 
Via The Motley Fool
News headline image
2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term ↗
Vertex Pharmaceuticals has given Mirum Pharmaceuticals the blueprint for success in rare diseases. 
Via The Motley Fool
News headline image
Is Vertex Pharmaceuticals' Empire in Trouble? ↗
It might not be too late to invest in this company. 
Via The Motley Fool
News headline image
1 S&P 500 Stock on Our Watchlist and 2 Facing Challenges
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec... 
Via StockStory
Topics Stocks
News headline image
Trump's Team Says Don't Worry About Rising Inflation. Here Are 3 Stocks to Buy If They're Wrong. ↗
Could the White House be overly optimistic about inflation? If so, you may want to own these stocks. 
Via The Motley Fool
Topics Economy Government
News headline image
Is This Biotech Stock Your Best Shot at Building a Millionaire-Making Position? ↗
With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has attracted a big Investor. 
Via The Motley Fool
Topics ETFs
News headline image
Vertex to Announce First Quarter 2026 Financial Results on May 4th
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have ou... 
Via StockStory
News headline image
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility
In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500... 
Via MarketMinute
Topics Economy Intellectual Property Stocks
News headline image
1 Cash-Producing Stock with Promising Prospects and 2 We Turn Down
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
77 78 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page